Is BEAM Regimen Augmentation Possible for Relapsed or Refractory Lymphoma?

Oncology NEWS InternationalOncology NEWS International Vol 13 No 8
Volume 13
Issue 8

The 14 reports in this special supplement discuss theuse of the cytoprotectant amifostine in patients withcancer of the head and neck, esophagus, lung, andcervix, as well as those with lymphoma and acutemyelogenous leukemia. Discussions focus on thepotential of this agent to both reduce radiation sideeffects such as xerostomia and permit doseescalation of chemotherapy and/or radiotherapy.Improvements in treatment outcome and quality oflife as a result of cytoprotection are examined.

ROCHESTER, NY-Currentstrategies using high-dose chemotherapy(HDC) and autologoushematopoietic stem cell transplantation(AHSCT) cure less than halfof in vivo patients with recurrentor resistant lymphoma, and drugresistance is the usual reason fortreatment failure. Attempts to increasethe dose of HDC/AHSCTregimens to address this problemhave been limited by regimen-relatedtoxicity (RRT) to variousorgans.Gordon L. Phillips II, MD, directorof the Blood and MarrowTransplant and Leukemia Program,Strong Health and James P.Wilmot Cancer Center, Rochester,New York and colleagues fromthe Medical College of Wisconsinare addressing this problem by assessingwhether the cytoprotectantamifostine (Ethyol) can reduceRRT to permit augmentation ofthe widely used BEAM (carmustine[BiCNU], etoposide (Ve-Pesid), ara-C [cytarabine; Cytosar-U], melphalan [Alkeran]) regimen."BEAM is the most widely usedHDC/AHSCT regimen for lymphoma,with acceptable nonrelapsemortality rates of less than 10%.[In BEAM, melphalan is given at140 mg/m2]. Toxicity is consid-ered acceptable if mortality ratesnot due to relapse are less than10%," Dr. Phillips said.Melphalan Dose Escalation
In other studies, single-agentmelphalan doses of 200 to 220 mg/m2 are the highest that can begiven-without cytoprotection-owing to mucosal RRT. Addingamifostine can permit increasedmelphalan doses of 280 mg/m2,Dr. Phillips said. "Thus, use of cytoprotectorsto minimize RRT ofexisting regimens might permitdose escalation, which might curemore patients."This concept is being tried in aphase I melphalan dose-escalationstudy using BEAM in whichmelphalan is escalated in 20mg/m2 increments in a cohortdesign. Amifostine was given at740 mg/m2 x 7.Dr. Phillips reported results forfour evaluable patients of thesix enrolled (four with non-Hodgkin's lymphoma, and twowith Hodgkin's lymphoma).ALL (acute lymphoblastic leukemia)engrafted and RRT was notnoted at the initial dose level; patientaccrual and dose escalationcontinues. "The need for multipledoses of amifostine was assumedbut is not proven," he said.The investigators concludedthat multiple-dose amifostine canbe given without severe problemsbut it is unclear if this reduces RRTbeyond the melphalan dose levelof 140 mg/m2.

Related Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Despite the addition of a TIGIT inhibitor to a checkpoint inhibitor resulting in high levels of safety, there is no future for that combination alone, according to Ritu Salani, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Following the results of the phase 3 CALLA trial, Jyoti S. Mayadev, MD, discusses the importance of global clinical multidisciplinary efforts in the locally advanced cervical cancer space.
Related Content